{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:35Z","timestamp":1791919475284,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.semarthrit.2014.05.007","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T15:15:11Z","timestamp":1399648511000},"page":"170-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Impaired response or insufficient dosage?\u2014Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout"],"prefix":"10.1016","volume":"44","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R.","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2014.05.007_bib1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/rheumatology\/ker361","article-title":"National prevalence of gout derived from administrative health data in Aotearoa New Zealand","volume":"51","author":"Winnard","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib3","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib4","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricaemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","article-title":"Rates of adherence and persistence with allopurinol therapy among gout patients in Israel","volume":"52","author":"Zandman-Goddard","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib10","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2474-13-174","article-title":"Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout","volume":"13","author":"Dalbeth","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib14","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","article-title":"A population pharmacokinetic model for allopurinol and oxypurinol in patients with gout","volume":"69","author":"Wright","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2125.1996.03116.x","article-title":"Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects","volume":"41","author":"Graham","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0009-8981(90)90107-4","article-title":"Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol","volume":"187","author":"Reiter","year":"1990","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0009-8981(99)00070-4","article-title":"A case of classical xanthinuria (type 1) with diabetes mellitus and Hashimoto\u05f3s thyroiditis","volume":"285","author":"Shibutani","year":"1999","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib18","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1007\/s00018-005-5269-y","article-title":"Molybdenum cofactor biosynthesis and deficiency","volume":"63","author":"Schwarz","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2036.2009.04057.x","article-title":"Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease","volume":"30","author":"Smith","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/dmd.111.043828","article-title":"The impact of single nucleotide polymorphisms on human aldehyde oxidase","volume":"40","author":"Hartmann","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib21","first-page":"467","article-title":"A map of human genome variation from population-scale sequencing","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.105.006056","article-title":"Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone","volume":"33","author":"Iwanaga","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","article-title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations","volume":"45","author":"Kottgen","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","article-title":"Understanding the dose-response relationship of allopurinol: predicting the optimal dosage","volume":"76","author":"Graham","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/FPC.0b013e3282f55e2e","article-title":"Functional characterization of human xanthine oxidase allelic variants","volume":"18","author":"Kudo","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib26","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI42344","article-title":"Uric acid transport and disease","volume":"120","author":"So","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","article-title":"The genetic basis of gout","volume":"78","author":"Merriman","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","article-title":"Human renal organic anion transporter 4 operates as an asymmetric urate transporter","volume":"18","author":"Hagos","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2011-201186","article-title":"A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study","volume":"72","author":"McAdams-Demarco","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.05.007_bib30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J Rheumatol"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2014.05.007_bib31","first-page":"448","article-title":"Adherence to EULAR recommendations for the treatment of gout","volume":"71","author":"Khanna","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T21:30:30Z","timestamp":1746221430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017214000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0049017214000778"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired response or insufficient dosage?\u2014Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}